Ocrelizumab (Ocrevus)

Ocrelizumab (Ocrevus) is covered only for adults (≥18) with FDA‑approved relapsing or primary progressive multiple sclerosis and is excluded for use in combination with other disease‑modifying MS agents or for non‑FDA‑approved indications. Coverage requires prescription by or consultation with an MS specialist/neurologist, documentation of diagnosis and age, adherence to the dosing schedule (300 mg IV x2, two weeks apart, then 600 mg IV every 6 months), and approvals are issued for 12 months.

"Not used in combination with other disease modifying MS agent(s)."

Sign up to see full coverage criteria, indications, and limitations.